Assembly Biosciences (ASMB) EBT Margin (2017 - 2026)
Assembly Biosciences (ASMB) recorded quarterly EBT Margin of 110.54% in Q1 2026, down 312.53% quarter-over-quarter from 52.01% in Q4 2025, and down 1692.0% on a YoY basis from 6.94% in Q1 2025.
Assembly Biosciences (ASMB) EBT Margin (2017 - 2026) Analysis & Trends
Assembly Biosciences' EBT Margin history runs 9 years deep, the most recent figure standing at 110.54% for Q1 2026.
- In Q1 2026, EBT Margin fell 1692.0% year-over-year to 110.54%; the TTM figure through Mar 2026 stood at 8.98% (up 11414.0% YoY), while the FY2025 annual figure was 8.47%, up 13125.0% from the prior year.
- EBT Margin was 110.54% for Q1 2026 at Assembly Biosciences, down from 52.01% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 52.01% in Q4 2025 to a low of 156.91% in Q1 2024.
- Historically, EBT Margin has averaged 106.07% across 4 years, with a median of 118.24% in 2024.
- The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 19353 bps in 2025, then plunged 1692 bps in 2026.
- A 4-year view of EBT Margin shows it stood at 152.58% in 2023, then grew by 7 bps to 141.51% in 2024, then soared by 137 bps to 52.01% in 2025, then plunged by 313 bps to 110.54% in 2026.
- The last three EBT Margin figures came in at 110.54% (Q1 2026), 52.01% (Q4 2025), and 85.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Assembly Biosciences | 418.96 Mn | 192.36 Mn | - | -110.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -110.54% |
| Dec 31, 2025 | 52.01% |
| Sep 30, 2025 | -85.23% |
| Jun 30, 2025 | -105.94% |
| Mar 31, 2025 | -93.62% |
| Dec 31, 2024 | -141.51% |
| Sep 30, 2024 | -140.44% |
| Jun 30, 2024 | -125.93% |
| Mar 31, 2024 | -156.91% |
| Dec 31, 2023 | -152.58% |
| Sep 30, 2021 | -300.66% |
| Dec 31, 2020 | -3,801.16% |
| Sep 30, 2020 | -9.68% |
| Jun 30, 2020 | 18.46% |
| Mar 31, 2020 | -653.15% |
| Dec 31, 2019 | -583.70% |
| Sep 30, 2019 | -591.11% |
| Jun 30, 2019 | -601.10% |
| Mar 31, 2019 | -696.50% |
| Dec 31, 2018 | -669.93% |